Reata Pharmaceuticals (RETA) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
50-Day Range
52-Week Range
1.99 million shs
Average Volume
1.09 million shs
Market Capitalization
$6.58 billion
P/E Ratio
Dividend Yield
Price Target

Reata Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
2.25 Rating Score
5.8% Downside
$162.44 Price Target
Short Interest
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($3.02) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.52 out of 5 stars

Medical Sector

861st out of 909 stocks

Pharmaceutical Preparations Industry

403rd out of 424 stocks

RETA stock logo

About Reata Pharmaceuticals Stock (NASDAQ:RETA)

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

RETA Stock News Headlines

How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
Top Growth Stocks for October 2023
How to camouflage a factory of 53,000 workers
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata Pharmaceuticals (RETA) Gets a Hold from Barclays
Biogen to Acquire Reata Pharmaceuticals
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
Expert Ratings for Reata Pharmaceuticals
See More Headlines
Receive RETA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reata Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
12 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$23.48 million
Book Value
($1.79) per share


Free Float
Market Cap
$6.58 billion

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

RETA Stock Analysis - Frequently Asked Questions

Should I buy or sell Reata Pharmaceuticals stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 9 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RETA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RETA, but not buy additional shares or sell existing shares.
View RETA analyst ratings
or view top-rated stocks.

What is Reata Pharmaceuticals' stock price target for 2024?

12 brokers have issued 1-year price targets for Reata Pharmaceuticals' stock. Their RETA share price targets range from $115.00 to $173.00. On average, they expect the company's stock price to reach $162.44 in the next twelve months. This suggests that the stock has a possible downside of 5.8%.
View analysts price targets for RETA
or view top-rated stocks among Wall Street analysts.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its quarterly earnings data on Monday, November, 8th. The company reported ($1.97) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.32) by $0.35. The firm had revenue of $7.40 million for the quarter, compared to analyst estimates of $2.07 million. The company's revenue was up 428.6% on a year-over-year basis. During the same period in the prior year, the business posted ($1.94) earnings per share.

What ETF holds Reata Pharmaceuticals' stock?

Subversive Mental Health ETF holds 111 shares of RETA stock, representing 2.00% of its portfolio.

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals Chief Executive Officer Warren Huff on Warren Huff has an approval rating of 92% among the company's employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

Reata Pharmaceuticals (RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.

This page (NASDAQ:RETA) was last updated on 4/24/2024 by Staff

From Our Partners